Lentiviral vectors (LVs) have become a cornerstone of gene therapy, particularly for ex vivo gene transfer applications, such as CAR-T therapies and stem cell modification. Their ability to integrate stably into the host genome makes them an ideal tool for durable therapeutic expression. However, this complexity introduces significant challenges to lentiviral vector manufacturing, including safety, scalability, and regulatory compliance.
Lentiviral Vector Production: Complex, Multistage, and Highly Regulated
The production of lentiviral vector involves multiple stages, including transient transfection or the use of producer cell lines, upstream cell culture expansion, vector harvest, and downstream purification. At every step, it is critical to maintain vector potency, remove host cell proteins and DNA, and confirm the absence of replication-competent lentivirus (RCL). These requirements necessitate specialized containment, rigorous analytical testing, and a deep understanding of the regulatory expectations from agencies such as the FDA and EMA.
Scalability Challenges in Lentiviral Vector Manufacturing
Scalability remains a significant challenge for both clinical-stage and commercial-stage gene therapy developers. Lentiviral vectors are typically produced using adherent or suspension HEK293-based systems, both of which require tight process control to minimize batch variability and prevent failure. At SK pharmteco, we apply both platform-based and custom process development strategies to support flexible batch sizes, whether you’re optimizing early-phase supply or preparing for commercial-scale production.
The Value of Working with a Specialized CDMO
Given the complexity of viral vector production, selecting a CDMO with dedicated expertise and capabilities in lentiviral vector manufacturing is essential. SK pharmteco offers a full suite of viral vector services, including plasmid DNA supply, cell banking, GMP-grade LV production, and analytical release testing. Our global facilities operate under stringent GMP conditions and are designed to meet the containment and quality control requirements unique to viral vectors.
Our team supports tech transfer, regulatory documentation, and comparability assessments to ensure your program can move confidently from development through commercialization. Whether you’re launching a first-in-human study or scaling up for commercial readiness, SK pharmteco is equipped to meet the evolving needs of gene therapy innovators.
Contact us to learn how our lentiviral vector capabilities can accelerate your path to market.